Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India

Asian Journal of Transfusion Science

Volumn 4, Issue 2, 2010, Pages 94-98

  Shah, Neeraj ^a   Mishra, Anupa ^a   Chauhan, Dhaval ^a   Vora, C ^b   Shah, N R ^a  

^a SMT NHL MUNICIPAL MEDICAL COLLEGE   (India)

^b Indian Red Cross Society Eye Bank   (India)

Author keywords

Beta thalassemia major; chelation; HCV positivity; iron overload

Indexed keywords

EID: 84859074017     PISSN: 09736247     EISSN: 19983565     Source Type: Journal    
DOI: 10.4103/0973-6247.67029     Document Type: Article

References (14)

1. Patel J, Patel A, Patel J, Kaur A, Patel V. Prevalence of haemoglobinopathies in Gujarat, India: A cross-sectional study. Int J Hematol. 2009;5:1.
2. Thalassemia International Federation: Guidelines for the clinical management of thalassemia. Available from: http://www.thalassaemia.org.cy/ Publications.htm [last accessed on 2004].
3. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007;31:S10-5.
4. Parikh SB, Parikh BJ, Shah CK, Shah NR. Analytical profile of seroprevalence of HIV, Hepatitis B and Hepatitis C amongst voluntary and replacement blood donors-a 6 years study. Gujarat M J 2006;1:29-33.
5. Agrawal MB, Malkan GH, Bhave AA, Vishwanathan C, Billa V, Dube SR, et al. Antibody to Hepatitis C virus in multi-transfused thalassemics-Indain experience. J Assoc Physicians India 1993;41:195-197
6. Arankalle VA, Chadha MS, Jha J, Amrapurkar DN, Banerjee K. Prevalence of anti-HCV antibodies in western India. Indian J Med Res 1995;101:91-93
7. Balgir RS. The burden of hemoglobinopathies in India and the challenges ahead. Curr Sci 2000;79:1536-1547
8. Verma IC, Choudhury VP, Jain PK. Prevention of thalassemia: A necessity in India. Indian J Pediatr 1992;59:649-654
9. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997;37:135-140
10. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of thalassemia major in North America. Blood 2004;104:34-39
11. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573
12. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al. Multi-Centre Study of Iron Overload Research Group: Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574-582
13. Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005;74:93-100.
14. Jaiswal SP, Chitnis DS, Jain AK, Inamdar S, Porwal A, Jain SC. Prevalence of hepatitis viruses among multi-transfused homogenous thalassaemia patients. Hepatol Res 2001;19:247-253